Insmed Incorporated (IM8N)
Summary
IM8N Chart
Insmed Tops Q2 Earnings Estimates, Stock Soars 34% on Brinsupri Uptake
INSM tops Q2 revenue and earnings estimates as strong Brinsupri uptake drives a 34% stock jump and prompts sharply higher 2026 sales guidance.
Insmed Q2 Earnings Call Highlights
Insmed NASDAQ: INSM reported second-quarter 2026 revenue growth driven by the continued launch of BRINSUPRI and steady sales of ARIKAYCE, while raising its full-year BRINSUPRI revenue outlook and increasing its long-term peak-sales estimates for its leading products.
Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcript
Insmed Incorporated (INSM) Q2 2026 Earnings Call Transcript
Insmed Incorporated (IM8N) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Insmed Incorporated ever had a stock split?
Insmed Incorporated Profile
| Pharmaceuticals Industry | Healthcare Sector | William H. Lewis CEO | XETRA Exchange | US4576693075 ISIN |
| US Country | 1,664 Employees | - Last Dividend | 3 Mar 2011 Last Split | 1 Jun 2000 IPO Date |
Overview
Insmed Incorporated stands as a pioneering biopharmaceutical entity, dedicated to the invention and commercialization of unique therapies intended for individuals grappling with serious and rare ailments across a global scale, including major markets like the United States, Europe, and Japan. With its inception in 1988, and headquartering in Bridgewater, New Jersey, the company has firmly positioned itself as a beacon of hope in the biopharmaceutical domain, channeling its expertise and resources towards addressing the unmet medical needs of patients burdened with rare diseases.
Products and Services
Insmed Incorporated’s portfolio is a testament to its commitment to innovation and patient care, featuring treatments that stand at the forefront of medical advancements for rare diseases. Among these are:
- ARIKAYCE - This groundbreaking therapy is designed for the treatment of Mycobacterium avium complex (MAC) lung disease and is administered as part of a combination antibacterial drug regimen tailored for adult patients. ARIKAYCE has emerged as a critical solution for those battling this complex condition, offering hope and improved health outcomes.
- Brensocatib - Currently under development, Brensocatib represents a novel approach in treating patients with bronchiectasis and other diseases driven by neutrophil malfunction. As an oral reversible inhibitor of dipeptidyl peptidase 1, Brensocatib has the potential to offer a new therapeutic option for managing these conditions, reflecting Insmed's ongoing innovation in battling rare diseases.
- Treprostinil Palmitil Inhalation Powder - This inhalation powder is an advanced formulation of a treprostinil prodrug, treprostinil palmitil, specifically designed for patients with pulmonary hypertension associated with interstitial lung disease (PH-ILD) and pulmonary arterial hypertension (PAH). This development underscores Insmed’s dedication to extending and enhancing the lives of those suffering from severe pulmonary conditions.
